Biomarkers for Diagnosis and Treatment of Chronic Obstructive Pulmonary Disease (COPD): What is the Role of microRNAs?

Authors

  • Luca Gallelli Department of Health Science, University of Catanzaro, Italy; Clinical Pharmacology and Pharmacovigilance Operative Unit, Mater Domini Hospital Catanzaro, Italy
  • Giacomo Leuzzi Department of General Medicine, Azienda Sanitaria Provinciale, Catanzaro, Italy
  • Antonio Scuteri Department of General Medicine, Azienda Sanitaria Provinciale, Catanzaro, Italy
  • Giuseppe Giuliano Department of General Medicine, Azienda Sanitaria Provinciale, Catanzaro, Italy
  • Paola Longo Department of Health Science, University of Catanzaro, Italy; Clinical Pharmacology and Pharmacovigilance Operative Unit, Mater Domini Hospital Catanzaro, Italy
  • Manuela Colosimo Central Laboratoy, Department of Medicine and Medical Specialties, Fondazione IRCCS Ospedale Maggiore Policlinico, Milano, Italy
  • Maria Cristina Caroleo Department of Pharmacy Nutrition and Health Sciences, University of Calabria, Rende (CS), Italy Chronic Obstructive Pulmonary Disease (COPD) is a heterogeneous respiratory dis- ease characterized by a progressive, not fully reversible airflow limitation associated with an abnormal inflammatory response of the lungs to noxious stimuli.
  • Erika Cione Department of Pharmacy Nutrition and Health Sciences, University of Calabria, Rende (CS), Italy Chronic Obstructive Pulmonary Disease (COPD) is a heterogeneous respiratory dis- ease characterized by a progressive, not fully reversible airflow limitation associated with an abnormal inflammatory response of the lungs to noxious stimuli.

DOI:

https://doi.org/10.17140/PRRMOJ-2-e002

Abstract

Chronic Obstructive Pulmonary Disease (COPD) is a heterogeneous respiratory dis-ease characterized by a progressive, not fully reversible airflow limitation associated with an abnormal inflammatory response of the lungs to noxious stimuli.

References

Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. The European Respiratory Journal. 2004; 23(6): 932-946. doi: 10.1183/09031936.04.00014304

Garvey C. Recent updates in chronic obstructive pulmonary disease. Postgraduate Medicine. 2015; 1-10. doi: 10.1080/0032 5481.2016.1118352

Vestbo J, Hurd SS, Agusti AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pul-monary disease: GOLD executive summary. American Journal of Respiratory and Critical Care Medicine. 2013; 187(4): 347-365. doi: 10.1164/rccm.201204-0596PP

Barnes PJ. Chronic obstructive pulmonary disease: effects beyond the lungs. PLoS Medicine. 2010; 7(3): e1000220. doi: 10.1371/ journal.pmed.1000220

Gan WQ, Man SFP, Senthilselvan A, Sin DD. Association between chronic obstructive pulmonary disease and systemic inflam-mation: a systematic review and a meta-analysis. Thorax. 2004; 59(7): 574-580. doi: 10.1136/thx.2003.019588

Pelaia G, Vatrella A, Busceti MT, et al. Pharmacologic rationale underlying the therapeutic effects of tiotropium/olodaterol in COPD. Ther Clin Risk Manag. 2015; 11: 1563-1572. doi: 10.2147/TCRM.S84151

Pelaia G, Terracciano R, Vatrella A, et al. Application of proteomics and peptidomics to COPD. BioMed Research International. 2014; 2014: 764581. doi: 10.1155/2014/764581

Watt J, Ganapathi P. COPD: Novel therapeutics and management strategies--SMi’s 7th Annual Conference (October 19-20, 2015--London, UK). Drugs Today (Barc). 2015; 51(10): 613-617. doi: 10.1358/dot.2015.51.10.2409817

Pelaia G, Vatrella A, Gallelli L, et al. Biological targets for therapeutic interventions in COPD: clinical potential. International Journal of Chronic Obstructive pulmonary disease. 2006; 1(3): 321-334.

Sarioglu N, Hismiogullari AA, Bilen C, Erel F. Is the COPD assessment test (CAT) effective in demonstrating the systemic inflammation and other components in COPD? Revista Portuguesa De Pneumologia. 2015.

Anderson P. Post-transcriptional regulons coordinate the initiation and resolution of inflammation. Nature Reviews Immunology. 2010; 10(1): 24-35. doi: 10.1038/nri2685

O’Connell RM, Rao DS, Baltimore D. microRNA regulation of inflammatory responses. Annual Review of Immunology. 2012; 30: 295-312. doi: 10.1146/annurev-immunol-020711-075013

Jiang X, Tsitsiou E, Herrick SE, Lindsay MA. MicroRNAs and the regulation of fibrosis. The FEBS Journal. 2010; 277(9): 2015- 2021. doi: 10.1111/j.1742-4658.2010.07632.x

Ramachandran S, Karp PH, Osterhaus SR, et al. Post-transcriptional regulation of cystic fibrosis transmembrane conductance regulator expression and function by microRNAs. American Journal of Respiratory Cell and Molecular Biology. 2013; 49(4): 544- 551. doi: 10.1165/rcmb.2012-0430OC

Stolzenburg LR, Wachtel S, Dang H, Harris A. microRNA-1343 attenuates pathways of fibrosis by targeting the TGF-beta recep-tors. The Biochemical Journal. 2015. doi: 10.1042/BJ20150821

Downloads

Published

2015-12-28

How to Cite

Luca Gallelli, Giacomo Leuzzi, Antonio Scuteri, Giuseppe Giuliano, Paola Longo, Manuela Colosimo, … Erika Cione. (2015). Biomarkers for Diagnosis and Treatment of Chronic Obstructive Pulmonary Disease (COPD): What is the Role of microRNAs?. Pulmonary Research and Respiratory Medicine, 2(4), e3-e5. https://doi.org/10.17140/PRRMOJ-2-e002

Issue

Vol. 2 No. 4 (2015): Volume 2 Issue 4 2015

Section

Articles

License

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All content published in Pulmonary Research and Respiratory Medicine (PRRM) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.